Degarelix vs standard androgen suppression therapy
Cardiovascular events · hormone‐sensitive prostate cancer
It is very uncertain whether degarelix changes cardiovascular events compared with standard androgen suppression therapy (very low certainty).
1 finding from 1 review
- Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes onlyRR 0.15 [0.04, 0.61]1 study · 80 participantsVery low